Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

A backlash against a White House video promoting deportation and Casalonga opening a new office in Düsseldorf were also among the top talking points ...

Eli Lilly has presented results from a trial in which Mounjaro measures up head-to-head against Trulicity in reducing cardiovascular risks.

Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two ...

On a tumultuous trading day, Eli Lilly and Co. (LLY) showcased a dramatic stock performance that belied its closing uptick. Starting the day with high hopes, the stock surged to a peak before plunging ...